{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,3]],"date-time":"2026-06-03T07:43:09Z","timestamp":1780472589238,"version":"3.54.1"},"reference-count":41,"publisher":"SAGE Publications","issue":"1","license":[{"start":{"date-parts":[[2015,4,30]],"date-time":"2015-04-30T00:00:00Z","timestamp":1430352000000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Bladder Cancer"],"published-print":{"date-parts":[[2015,4,30]]},"abstract":"<jats:sec>\n                    <jats:title>Purpose:<\/jats:title>\n                    <jats:p>Despite recent improvements, resistance to traditional immunotherapy or chemotherapy is still common in patients with bladder cancer. We constructed an oncolytic virus from herpes simplex virus type II (HSV-2), which selectively targets tumor cells with an activated Ras signaling pathway. We evaluated the antitumor effect of this oncolytic HSV-2 (FusOn-H2) against bladder cancer, and compared with that of a first generation oncolytic virus derived from HSV-1 (Baco-1).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Materials and methods:<\/jats:title>\n                    <jats:p>We established bladder tumor at the orthotopic site in C3H\/He mice using the MBT-2 cells. Baco-1 or FusOn-H2 was instilled into the bladder through the urethra respectively. Tumor volume and weight were recorded by the end of the experiment. Animal spleens were also collected to determine if any anti-tumor immunity was elicited during virotherapy in this syngeneic bladder cancer model.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>Two instillations of the oncolytic HSVs into bladder of tumor-bearing mice almost completely eradicated the tumor in majority of tumor bearing mice. The results of tumor-specific cytotoxic T lymphocyte activity assay showed that tumor destruction by oncolytic viruses in vivo, especially by the FusOn-H2, induced potent anti-tumor immune responses.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion:<\/jats:title>\n                    <jats:p>Oncolytic virus derived from HSV-2 has potent anti-tumor activity against bladder cancer. Oncolytic effect of this virus in vivo induces tumor specific cellular immunity that further enhances the overall anti-tumor activity. Translating this novel virotherapy into the clinic could present an alternative intravesical therapy strategy for patients with bladder cancer.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3233\/blc-150013","type":"journal-article","created":{"date-parts":[[2015,5,29]],"date-time":"2015-05-29T05:14:18Z","timestamp":1432876458000},"page":"81-90","source":"Crossref","is-referenced-by-count":5,"title":["Therapeutic Effect on Bladder Cancer with a\u00a0Conditionally Replicating Oncolytic Virus Derived from Type II Herpes Simplex Virus"],"prefix":"10.1177","volume":"1","author":[{"given":"Kwan Joong","family":"Joo","sequence":"first","affiliation":[{"name":"Scott Department of Urology, Baylor College of Medicine, Houston, TX, USA"},{"name":"Department of Urology, Kangbuk Samsung Hospital, Sungkyunkwan University School of Medicine, Seoul, South Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hongtao","family":"Li","sequence":"additional","affiliation":[{"name":"Department of Pediatrics, Baylor College of Medicine, Houston, TX, USA"},{"name":"Center for Cell and Gene Therapy, and Baylor College of Medicine, Houston, TX, USA"},{"name":"Department of Molecular Medicine, Mayo Clinic, Rochester, MN, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoliu","family":"Zhang","sequence":"additional","affiliation":[{"name":"Department of Pediatrics, Baylor College of Medicine, Houston, TX, USA"},{"name":"Center for Cell and Gene Therapy, and Baylor College of Medicine, Houston, TX, USA"},{"name":"Department of Molecular Virology and Microbiology, Baylor College of Medicine, Houston, TX, USA"},{"name":"Department of Biology and Biochemistry and Center for Nuclear Receptors and Cell Signaling, University of Houston, Houston, TX, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Seth P.","family":"Lerner","sequence":"additional","affiliation":[{"name":"Scott Department of Urology, Baylor College of Medicine, Houston, TX, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"179","published-online":{"date-parts":[[2015,4,30]]},"reference":[{"key":"r1","unstructured":"JemalASiegelRWardEHaoYXuJMurrayT2008Cancer statistics, CA Cancer J Clin587196"},{"key":"r2","doi-asserted-by":"publisher","DOI":"10.1016\/S0022-5347(05)66518-4"},{"key":"r3","unstructured":"MalmstromPUWijkstromHLundholmCWesterKBuschCNorlenBJ19995-year followup of a randomized prospective study comparing mitomycin C and bacillus Calmette-Guerin in patients with superficial bladder carcinomaSwedish-Norwegian Bladder Cancer Study GrouJ Urol16111241127"},{"key":"r4","doi-asserted-by":"publisher","DOI":"10.1038\/nrc1750"},{"key":"r5","doi-asserted-by":"publisher","DOI":"10.1038\/nm0995-938"},{"key":"r6","doi-asserted-by":"publisher","DOI":"10.1097\/00000658-199609000-00008"},{"key":"r7","doi-asserted-by":"publisher","DOI":"10.1089\/hum.1998.9.15-2177"},{"key":"r8","doi-asserted-by":"publisher","DOI":"10.1089\/10430349950017211"},{"key":"r9","doi-asserted-by":"publisher","DOI":"10.1089\/10430349950016410"},{"key":"r10","unstructured":"PawlikTMNakamuraHYoonSSMullenJTChandrasekharSChioccaEA2000Oncolysis of diffuse hepatocellular carcinoma by intravascular administration of a replication-competent, genetically engineered herpesvirusCancer Res6027902795"},{"key":"r11","unstructured":"NakamoriMFuXMengFJinATaoLBastRCJr2003Effective therapy of metastatic ovarian cancer with an oncolytic herpes simplex virus incorporating two membrane fusion mechanismsClin Cancer Res927272733"},{"key":"r12","doi-asserted-by":"publisher","DOI":"10.1089\/10430340050111331"},{"key":"r13","doi-asserted-by":"publisher","DOI":"10.1016\/j.urology.2005.05.041"},{"key":"r14","doi-asserted-by":"publisher","DOI":"10.1096\/fj.00-0533fje"},{"key":"r15","unstructured":"MinetaTRabkinSDMartuzaRL1994Treatment of malignant gliomas using ganciclovir-hypersensitive, ribonucleotide reductase-deficient herpes simplex viral mutantCancer Res5439633966"},{"key":"r16","doi-asserted-by":"publisher","DOI":"10.1006\/viro.1995.1382"},{"key":"r17","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.93.21.11313"},{"key":"r18","unstructured":"PennisiE1996Will a twist of viral fate lead to a new cancer treatment? Science274342343"},{"key":"r19","doi-asserted-by":"publisher","DOI":"10.1038\/nm1297-1323"},{"key":"r20","doi-asserted-by":"publisher","DOI":"10.1006\/excr.1999.4623"},{"key":"r21","doi-asserted-by":"publisher","DOI":"10.1128\/jvi.63.8.3389-3398.1989"},{"key":"r22","doi-asserted-by":"publisher","DOI":"10.1128\/JVI.74.22.10417-10429.2000"},{"key":"r23","doi-asserted-by":"publisher","DOI":"10.1038\/35087061"},{"key":"r24","doi-asserted-by":"publisher","DOI":"10.1016\/j.ymthe.2006.02.007"},{"key":"r25","doi-asserted-by":"publisher","DOI":"10.1016\/j.urology.2006.04.021"},{"key":"r26","doi-asserted-by":"publisher","DOI":"10.1002\/pros.20056"},{"key":"r27","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-06-0045"},{"key":"r28","doi-asserted-by":"publisher","DOI":"10.1086\/314065"},{"key":"r29","doi-asserted-by":"publisher","DOI":"10.1016\/S0022-5347(17)35678-1"},{"key":"r30","unstructured":"GrossmanHBO\u2019DonnellMACooksonMSGreenbergREKeaneTE2008Bacillus calmette-guerin failures and beyond: Contemporary management of non-muscle-invasive bladder cancerRev Urol10281289"},{"key":"r31","doi-asserted-by":"publisher","DOI":"10.1016\/S0022-5347(05)65755-2"},{"key":"r32","doi-asserted-by":"publisher","DOI":"10.1097\/01.ju.0000142657.62689.f6"},{"key":"r33","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-05-1059"},{"key":"r34","doi-asserted-by":"publisher","DOI":"10.1097\/01.ju.0000088670.02905.78"},{"key":"r35","doi-asserted-by":"publisher","DOI":"10.1016\/0046-8177(92)90285-B"},{"key":"r36","unstructured":"FuXZhangX2002Potent systemic antitumor activity from an oncolytic herpes simplex virus of syncytial phenotypeCancer Res6223062312"},{"key":"r37","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-03-3753"},{"key":"r38","doi-asserted-by":"publisher","DOI":"10.1128\/JVI.76.3.1435-1449.2002"},{"key":"r39","unstructured":"BatemanARHarringtonKJKottkeTAhmedAMelcherAAGoughMJ2002Viral fusogenic membrane glycoproteins kill solid tumor cells by nonapoptotic mechanisms that promote cross presentation of tumor antigens by dendritic cellsCancer Res6265666578"},{"key":"r40","doi-asserted-by":"publisher","DOI":"10.1002\/jgm.1005"},{"key":"r41","doi-asserted-by":"publisher","DOI":"10.1016\/S0092-8674(01)00449-4"}],"container-title":["Bladder Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.3233\/BLC-150013","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.3233\/BLC-150013","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.3233\/BLC-150013","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,28]],"date-time":"2026-04-28T13:22:51Z","timestamp":1777382571000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.3233\/BLC-150013"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,4,30]]},"references-count":41,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2015,4,30]]}},"alternative-id":["10.3233\/BLC-150013"],"URL":"https:\/\/doi.org\/10.3233\/blc-150013","relation":{},"ISSN":["2352-3727","2352-3735"],"issn-type":[{"value":"2352-3727","type":"print"},{"value":"2352-3735","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,4,30]]}}}